10-K: Precigen Secures Full FDA Approval for Papzimeos, Shifts Focus to Commercialization

Precigen achieved a significant milestone with full FDA approval for Papzimeos, its first commercial product for recurrent respiratory papillomatosis, as it navigates substantial financial losses and strategic pipeline adjustments.

Summary

• Precigen received full FDA approval in August 2025 for Papzimeos (zopapogene imadenovec-drba, PRGN-2012) for the treatment of adults with recurrent respiratory papillomatosis (RRP), making it the first and only FDA-approved therapy for this condition.
• The pivotal study for Papzimeos demonstrated a 51% (18 out of 35 patients) complete response rate, with responses durable for over 12 months (median 36 months for 15 patients).
• The company has strategically prioritized its pipeline, pausing enrollment in PRGN-3005 and PRGN-3007 UltraCAR-T clinical trials and minimizing UltraCAR-T spending.
• PRGN-2009 Phase 2 clinical trials continue under a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) for HPV-associated cancers.
• ActoBio's operations were shut down in 2024, and its intellectual property is now available for prospective transactions.
• Precigen reported a net loss of $250.6 million in 2025, an increase from $126.2 million in 2024, primarily due to a $139.5 million increase in the fair value of warrant liabilities and a $179.0 million non-cash deemed dividend on preferred stock.
• Commercial readiness efforts for Papzimeos are underway, including a contracted sales force, established patient support program, and secured private health plan coverage for approximately 215 million lives, plus Medicare and Medicaid.
• The company secured a 5-year senior secured term loan facility of up to $125.0 million in September 2025, with an initial tranche of $100.0 million funded.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but cautiously optimistic filing. The full FDA approval and successful commercial launch of Papzimeos are significant positive catalysts, demonstrating the company's ability to bring a product to market. However, substantial net losses, increased commercialization expenses, and the strategic pausing of other pipeline programs indicate ongoing financial challenges and a narrowed strategic focus.

Positives

• Papzimeos (PRGN-2012) received full FDA approval in August 2025 for adults with RRP, eliminating the need for a confirmatory clinical trial.
• The pivotal study for Papzimeos met primary safety and efficacy endpoints, showing a 51% complete response rate (18 out of 35 patients) with durable responses (median 36 months for 15 patients).
• Papzimeos was well-tolerated with no dose-limiting toxicities or treatment-related adverse events greater than Grade 2.
• The company achieved a successful commercial launch of Papzimeos in the US, with early demand consistent with internal expectations.
• Secured private health plan coverage for approximately 215 million lives, including most leading insurers, and coverage under Medicare and Medicaid for Papzimeos.
• PRGN-3006 UltraCAR-T Phase 1/1b trial showed PRGN-3006 was well-tolerated with no dose-limiting toxicities (DLTs) and excellent dose-dependent expansion and persistence.
• PRGN-3006 achieved an objective response rate (ORR) of 27% (3 out of 11) and a disease control rate (DCR) of 45% (5 out of 11) in heavily pre-treated r/r AML patients in the lymphodepletion cohort.
• Identified clinical biomarkers correlating to objective responses after PRGN-3006 treatment, potentially enabling patient stratification and improved efficacy.
• Secured a 5-year senior secured term loan facility of up to $125.0 million in September 2025, with $100.0 million funded, providing additional liquidity.
• UltraPorator, a proprietary electroporation device, has FDA clearance as a manufacturing device for UltraCAR-T investigational therapies.

Negatives

• Reported a net loss of $250.6 million for the year ended December 31, 2025, a significant increase from $126.2 million in 2024.
• Accumulated deficit reached $2.3 billion as of December 31, 2025.
• Total other expense, net, changed from income of $7.0 million in 2024 to an expense of $140.1 million in 2025, primarily due to a $139.5 million increase in the fair value of warrant liabilities.
• Recorded a $179.0 million non-cash deemed dividend on preferred stock upon conversion in September 2025, increasing net loss attributable to common shareholders.
• Strategic prioritization led to pausing enrollment in PRGN-3005 and PRGN-3007 UltraCAR-T clinical trials and minimizing UltraCAR-T spending.
• Shutdown of ActoBio's operations in 2024, resulting in impairment charges and reclassification of cumulative foreign currency translation losses.
• Incurred a $3.9 million goodwill impairment charge related to the Exemplar reporting unit in 2025.
• Selling, general and administrative expenses increased by $28.8 million (69.8%) in 2025, primarily due to Papzimeos commercialization efforts.
• The company has limited experience as a commercial company and faces risks in successfully commercializing Papzimeos.
• The company is substantially dependent on the commercial success of Papzimeos.

Risks

• Substantial dependence on the commercial success of Papzimeos.
• History of net losses and may not achieve or maintain profitability.
• Expectation of substantial future capital requirements dependent on many factors, including Papzimeos sales and R&D progress.
• Level of indebtedness and debt service obligations could adversely affect financial condition and make funding operations more difficult.
• Failure of the U.S. federal government to manage fiscal matters or raise/suspend the debt ceiling may expose the company to increased financial and operational risk.
• Market opportunities for products and product candidates may be smaller than estimated.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, potentially delaying or denying commercialization.
• Clinical development is lengthy and expensive with uncertain outcomes, potentially incurring additional costs or delays.
• Limited experience designing and implementing clinical trials, which could lead to adverse effects, increased costs, and delayed timelines.
• Cell and gene therapies are novel, complex, and difficult to manufacture.
• Interim and preliminary clinical trial results may change, leading to material changes in final data.
• Prioritization of certain product candidates may lead to expending resources on unsuccessful products or failing to capitalize on more profitable opportunities.
• Products may fail to achieve market acceptance by physicians, patients, and third-party payers.
• Delays in obtaining regulatory approval of manufacturing processes/facilities or disruptions in manufacturing may delay commercialization.
• Failure to maintain a manufacturing supply chain for Papzimeos could severely harm business.
• Reliance on third parties for certain aspects of manufacturing increases risk of insufficient quantities or unacceptable costs.
• Ongoing regulatory obligations and review post-marketing approval may result in significant additional expense.
• Limited experience as a commercial company, potentially leading to unsuccessful or less successful sales, marketing, and distribution.
• Successful commercialization depends on third-party payer coverage and adequate reimbursement levels.
• Failure to comply with privacy and data protection laws could lead to enforcement actions, litigation, and adverse publicity.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reporting or fraud.
• Risk of product liability lawsuits.
• Insurance policies are expensive and may not cover all business risks, leaving significant uninsured liabilities.
• Competitors may develop obsolete products/technologies or garner greater market share.
• Loss of key personnel or inability to attract/retain additional personnel could delay programs and harm R&D.
• Significant breach of data security or disruption in information systems could adversely affect business.
• Inadequate protection of proprietary technologies or loss of intellectual property rights through costly litigation or administrative proceedings.
• Litigation or third-party claims of intellectual property infringement could be costly and prevent commercialization.
• Enforcing intellectual property rights may be difficult and unpredictable, especially internationally.
• Failure to meet Nasdaq Global Select Market listing requirements could result in delisting.
• Quarterly and annual operating results may fluctuate, potentially causing stock price decline.
• Stock price is volatile, and purchasers could incur substantial losses.
• Randal J. Kirk's significant control (approximately 34% of common stock as of February 15, 2026) may influence shareholder votes and corporate actions.
• Sales of a substantial number of common stock shares in the public market could cause the market price to drop significantly.
• Anti-takeover provisions in articles of incorporation, bylaws, and Virginia law could delay or prevent an acquisition.
• The livestock products of Exemplar are subject to disease outbreaks that can increase the cost of production and/or reduce production harvests.
• Use of new and evolving technologies, such as artificial intelligence, may present cybersecurity, data privacy, intellectual property, regulatory, legal, operational, competitive, and reputational risks.

Future Outlook

The company plans to continue advancing its lead clinical-stage programs and strategically pursuing preclinical programs, leveraging its technology platforms across indications. It intends to efficiently pursue these programs toward clinical proof-of-concept and commercialization, whether independently or with collaborators. The company expects future revenue to primarily be generated from Papzimeos product sales and anticipates collaboration revenue to remain minimal unless new strategic transactions occur. Research and development expenditures are expected to increase as healthcare programs and platforms advance. Management believes existing cash, cash equivalents, short and long-term investments, combined with anticipated potential revenue from the commercialization of Papzimeos, will enable operations for at least one year from the filing date. The company plans to focus on strategic partnership opportunities to advance the PRGN-3006 UltraCAR-T program in AML and is preparing for an end of Phase 1b meeting with the FDA to discuss results and next steps.

Management Comments

• "We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine."
• "We exercise discipline in our portfolio management by systematically evaluating data from our preclinical programs in order to make rapid 'go' and 'no go' decisions."
• "Through this process, we believe we can more effectively allocate resources to programs that we believe show the most promise and advance such programs to clinical trials."
• "The Papzimeos approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP."
• "Papzimeos early demand is consistent with internal expectations, with patients being treated nationwide within IDN and community settings."
• "We believe UltraCAR-T is the only autologous CAR-T platform with manufacturing, quality control release and infusion back to the patient, occurring in one day."
• "Management believes that its existing cash, cash equivalents and short and long-term investments, combined with anticipated potential revenue from the commercialization of Papzimeos, will enable us to continue our operations for at least one year from the date of this filing."

Industry Context

StockSavvy.ai notes that Precigen's full FDA approval of Papzimeos for RRP positions it as a pioneer in a rare disease market with no prior approved therapies, a significant competitive advantage. This aligns with a broader industry trend towards precision medicine and targeted therapies for unmet medical needs. However, the company's strategic decision to pause other UltraCAR-T programs (PRGN-3005, PRGN-3007) and seek partnerships for PRGN-3006 reflects the high capital intensity and risk associated with advanced cell and gene therapies, a common challenge for smaller biopharmaceutical firms. The competitive landscape for HPV-associated cancers and CAR-T therapies remains intense, with numerous established players and emerging biotechs developing competing approaches, highlighting the need for strong differentiation and efficient commercialization.

Comparison to Industry Standards

• Papzimeos is the first and only FDA-approved therapy for adults with RRP, setting a new standard in a previously underserved rare disease market. Competitors like INOVIO Pharmaceuticals (INO-3107) are developing DNA vaccines for HPV6/11, but Papzimeos has achieved market entry first.
• The UltraCAR-T platform's rapid, overnight, decentralized manufacturing process, enabled by UltraPorator, aims to disrupt the CAR-T landscape by addressing the complex, lengthy, and costly manufacturing limitations of traditional CAR-T therapies (e.g., those from Novartis, Kite/Gilead, Bristol-Myers Squibb). This approach offers a potential competitive advantage in speed and accessibility.
• PRGN-3006's objective response rate of 27% and disease control rate of 45% in heavily pre-treated r/r AML patients in the lymphodepletion cohort provides early clinical evidence in a challenging indication, where competitors like Essen Biotech, Senti Bio, and Allogene Therapeutics are also developing cell therapies.
• The company's history of net losses and accumulated deficit of $2.3 billion is common for early-stage biopharmaceutical companies with high R&D costs, but the significant increase in net loss in 2025 due to warrant liabilities and deemed dividends is a notable financial event.

Corporate Governance

Legal Proceedings

• A derivative shareholder action, captioned Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al, was filed in December 2020 and stayed on June 14, 2021, related to disclosures about the MBP program.
• An individual shareholder lawsuit, Kent v. Precigen, Inc., was filed on September 24, 2021, demanding inspection of certain books and records related to the MBP program, with a demurrer denied on April 1, 2022.
• The company is involved in other litigation and legal matters in the course of its business, but does not believe any such matters, individually or in the aggregate, will have a material adverse effect on its business, financial condition, results of operations, or cash flows as of December 31, 2025.

Related Party Transactions

• Randal J. Kirk, Executive Chairman and affiliated shareholders, beneficially owned approximately 34% of the company's voting stock as of February 15, 2026.
• Executive officers and directors, as a group, owned approximately 37% of the company's voting common stock as of February 15, 2026.
• In August 2024, related parties and their affiliates, including the Chairman of the Board and one executive officer, purchased 23,588,234 shares in a public offering.
• In January 2023, related parties and their affiliates, including the CEO, Chairman, and other officers, purchased 11,517,712 shares in a public offering.
• The company has historically owned equity interests in its collaborators, increasing exposure to the risks of those collaborators' businesses.

Stakeholder Impact

• Shareholders face potential for dilution from future equity financings, stock price volatility, reliance on stock appreciation for return as no cash dividends are anticipated, significant influence of Randal J. Kirk, and anti-takeover provisions.
• Patients with RRP benefit from improved outcomes due to the first FDA-approved therapy, Papzimeos, and there is potential for new precision medicines in immuno-oncology, autoimmune disorders, and infectious diseases.
• Employees experienced a workforce reduction in August 2024 as part of strategic prioritization; compensation packages include competitive base salary, bonus, equity incentives, 401(k), and health/wellness benefits, along with ongoing employee development initiatives.
• Healthcare providers and payers gain a new treatment option (Papzimeos) for RRP, but coverage and adequate reimbursement from third-party payers remain critical for market access.
• Creditors hold obligations under the $125.0 million senior secured term loan facility, which is secured by substantially all of the company's U.S. assets.

Next Steps

• Continue commercialization of Papzimeos in the United States.
• Seek regulatory approval for Papzimeos in the European Union (MAA submitted November 2025, currently under review).
• Continue PRGN-2009 Phase 2 clinical trials under CRADA with NCI in recurrent/metastatic cervical cancer and newly diagnosed HPV-associated oropharyngeal cancer.
• Prepare for an end of Phase 1b meeting with the FDA to discuss results and next steps for PRGN-3006.
• Focus on strategic partnership opportunities to advance the PRGN-3006 UltraCAR-T program in AML.
• Evaluate internal and external strategies to support cGMP manufacturing needs for AdenoVerse-based therapeutics.
• Continue development of select preclinical programs to create long-term value.
• Make final payments for indemnification claims related to the Trans Ova subsidiary sale in 2026.
• Helen Sabzevari's stock trading plan first sale will not occur until March 31, 2026, at the earliest, and is scheduled to terminate on December 31, 2026.

Key Dates

Recommendation

Precigen's full FDA approval and commercial launch of Papzimeos for RRP is a significant positive catalyst, establishing the company in a rare disease market. However, this milestone is overshadowed by substantial net losses, increased commercialization expenses, and the strategic pausing of other pipeline programs, indicating ongoing financial pressures and a narrowed strategic focus. While the long-term potential of Papzimeos and the underlying technology platforms exists, the current financial performance and execution risks warrant a cautious 'hold' stance for investors to observe the commercial ramp-up and financial trajectory.

Keywords

Biopharmaceutical, Gene Therapy, Cell Therapy, Immuno-oncology, Autoimmune Disorders, Infectious Diseases, RRP, Recurrent Respiratory Papillomatosis, Papzimeos, PRGN-2012, AdenoVerse, UltraCAR-T, PRGN-2009, PRGN-3006, HPV-associated cancers, AML, Acute Myeloid Leukemia, UltraPorator, FDA Approval, Commercialization, Precision Medicine, Biotechnology, SEC Filing, 10-K